MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2017 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
51.7 M |
Market Cap[1] |
$ 370 M |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MannKind Corporation
MNKD
|
$ 3.04 | 5.63 % | $ 929 M | Nasdaq Global Market | USA |
 |
Mersana Therapeutics
MRSN
|
- | - | $ 3.56 B | Nasdaq Global Select Market | USA |
 |
Evelo Biosciences
EVLO
|
- | -14.46 % | $ 27.9 M | Nasdaq Global Select Market | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
- | - | $ 384 M | Nasdaq Global Select Market |  Britain |
 |
Morphic Holding
MORF
|
- | - | $ 2.42 B | Nasdaq Global Market | USA |
 |
Monopar Therapeutics
MNPR
|
$ 69.27 | 1.42 % | $ 513 M | Nasdaq Global Select Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Genocea Biosciences
GNCA
|
- | -15.0 % | $ 3.04 M | Nasdaq Global Select Market | USA |
|
Amryt Pharma plc
AMYT
|
- | - | $ 621 M | Nasdaq Global Select Market | Britain |
 |
Milestone Pharmaceuticals
MIST
|
$ 0.71 | 0.84 % | $ 75.4 M | Nasdaq Global Select Market |  Canada |
 |
Kinnate Biopharma
KNTE
|
- | - | $ 123 M | Nasdaq Global Select Market | USA |
 |
Atossa Therapeutics
ATOS
|
$ 2.91 | 9.81 % | $ 25.1 M | Nasdaq Capital Market | USA |
 |
NexImmune
NEXI
|
- | 70.13 % | $ 4.12 M | Nasdaq Global Market | USA |
 |
Merck & Co.
MRK
|
$ 145.95 | 0.52 % | $ 365 B | NYSE,SPB | USA |
 |
Marker Therapeutics
MRKR
|
$ 1.04 | 13.04 % | $ 15.9 M | Nasdaq Global Market | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
- | -9.21 % | $ 2.55 M | Nasdaq Global Market | USA |
 |
Maravai LifeSciences Holdings
MRVI
|
$ 6.79 | 7.94 % | $ 980 M | Nasdaq Global Select Market | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
- | -19.68 % | $ 18.4 M | Nasdaq Capital Market | Canada |
 |
Abeona Therapeutics
ABEO
|
$ 4.43 | 6.65 % | $ 235 M | Nasdaq Capital Market | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 19.12 | 2.39 % | $ 3.22 B | Nasdaq Global Select Market,SPB | USA |
 |
Matinas BioPharma Holdings
MTNB
|
$ 2.37 | 0.83 % | $ 13 M | NYSE American | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
$ 4.63 | 21.05 % | $ 20 M | Nasdaq Capital Market |  Israel |
 |
IGM Biosciences
IGMS
|
- | - | $ 76.9 M | Nasdaq Global Select Market,SPB | USA |
 |
IMV
IMV
|
- | - | $ 13.1 M | Nasdaq Global Select Market | Canada |
 |
Karuna Therapeutics
KRTX
|
- | - | $ 12.2 B | Nasdaq Global Market,SPB | USA |
 |
Chimerix
CMRX
|
- | - | $ 756 M | Nasdaq Global Select Market | USA |
 |
Neurocrine Biosciences
NBIX
|
$ 135.71 | 0.68 % | $ 13.5 B | Nasdaq Global Select Market,SPB | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 231.83 | 0.11 % | $ 30.4 B | Nasdaq Global Select Market,SPB | USA |
 |
NuCana plc
NCNA
|
$ 0.99 | 0.98 % | $ 11.1 B | Nasdaq Global Select Market | Britain |
 |
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | USA |
 |
Burford Capital Limited
BUR
|
$ 3.0 | 0.15 % | $ 657 M | NYSE | Britain |
 |
Aprea Therapeutics
APRE
|
$ 0.58 | 2.27 % | $ 3.79 M | Nasdaq Global Select Market,SPB | USA |
 |
LogicBio Therapeutics
LOGC
|
- | - | $ 229 M | Nasdaq Global Market | USA |
 |
AnaptysBio
ANAB
|
$ 46.61 | 4.37 % | $ 1.35 B | Nasdaq Global Select Market,SPB | USA |
 |
Anika Therapeutics
ANIK
|
$ 19.98 | 2.17 % | $ 286 M | Nasdaq Global Select Market,SPB | USA |
 |
Minerva Neurosciences
NERV
|
$ 2.35 | 2.98 % | $ 19.9 M | Nasdaq Global Market | USA |
 |
Merrimack Pharmaceuticals
MACK
|
- | - | $ 216 M | Nasdaq Global Market | USA |
 |
BioXcel Therapeutics
BTAI
|
$ 0.07 | 9.81 % | $ 855 K | Nasdaq Global Select Market,SPB | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 10.34 | 1.35 % | $ 283 M | Nasdaq Global Market,SPB | Israel |
 |
argenx SE
ARGX
|
$ 819.14 | 3.42 % | $ 50.2 B | Nasdaq Global Select Market |  Niderland |
|
89bio
ETNB
|
- | - | $ 1.55 B | Nasdaq Global Market | USA |
 |
Bristol-Myers Squibb Company
BMY
|
$ 59.75 | 0.12 % | $ 122 B | NYSE,SPB | USA |
 |
Nkarta
NKTX
|
$ 1.8 | 1.35 % | $ 133 M | Nasdaq Global Select Market | USA |
 |
Cabaletta Bio
CABA
|
$ 1.41 | 0.5 % | $ 142 M | Nasdaq Global Select Market | USA |
 |
Fusion Pharmaceuticals
FUSN
|
- | - | $ 1.41 B | Nasdaq Global Select Market | Canada |
 |
CytomX Therapeutics
CTMX
|
$ 2.28 | 8.07 % | $ 314 M | Nasdaq Global Select Market | USA |
 |
Mirati Therapeutics
MRTX
|
- | - | $ 3.3 B | Nasdaq Global Select Market,SPB | USA |
 |
Novavax
NVAX
|
$ 11.26 | 1.42 % | $ 1.82 B | Nasdaq Global Select Market | USA |
 |
Novo Nordisk A/S
NVO
|
$ 38.83 | 0.14 % | $ 173 B | NYSE |  Danmark |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.